Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03110822 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.

NCT NCT03110822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Lead sponsor
Oncotherapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
February 1, 2017
Completion date
February 28, 2027
Enrollment
134 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma